UK markets open in 7 hours 2 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.21-0.43 (-3.69%)
At close: 4:00PM EDT
Sign in to post a message.
  • U
    USA
    Upgraded 7 out of 7 strong buy $28 price target with $35 high (see link)

    Check out AERI Analyst Price Target $28.57 on TipRanks http://www.tipranks.com/ios/pages/stocks/AERI/price-target
  • R
    Rod
    "The company is therefore projected to breakeven around 3 years from today. (The "today" being August 21, 2020. https://finance.yahoo.com/news/aerie-pharmaceuticals-inc-nasdaq-aeri-130116850.html What response from pumpers and dumpers here?
  • V
    Vs
    My bottle count was spot on. While revenue $18 due to lower per bottle cost, Important part is volume and market share. Both they are gaining.

    I think once they have very good coverage on Medicare D, We may acheive 15% market share very easily in just 2 year.
    So What 15% share even at $70 Bottle would look like in USA?
    We talking about 8M bottle x 70 = $560M

    So bottles are way more important than per bottle price. I think keeping lower price they can gain market share quickly as payer would have less resistant to go for cheaper alternative.
  • T
    Tiger
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Aerie Pharma (NASDAQ: AERI), Bristol Myers (NYSE: BMY) and Brainsway (NASDAQ: BWAY) | Analyst Ratings
    www.google.com
  • T
    Tiger
    Long-Term Investors Should Consider Buying the Dips in Aerie Pharmaceuticals Inc. [AERI] Stock | MZP News
    www.google.com
  • V
    Vs
    My calculation based on their presentation chart put total around 230K bottle
    We going to have $19M+ in revenue this quarter ($85/bottle rate) which actually very very good given all Eye clinic have impact due to covid 19.

    I think recent script data indicate inflection point much closer for Rockalatan. Covid19 may be keeping it from going much higher but given how important Glucoma treatment, it will sell.
  • D
    David
    Well....At least Oppenheimer is maintaining an Outperform rating and $24 price target, while Needham - on July 17th, assigned AERI a BUY rating and price target of 32... so....there's THAT. Here is the link: https://www.markets.co/analysts-offer-insights-on-healthcare-companies-aerie-pharma-nasdaq-aeri-and-quest-diagnostics-nyse-dgx/262565/
    Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI – Research
    Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI – Research
    www.markets.co
  • D
    David
    October 2013...price $10.50..... almost Seven years later and the price is $12.10....hummm so much for Long-Term investments here, right JIM.?
  • m
    mike
    Best news we have is analysts lowering their price targets.... needs to be above fifteen by next Fridays close or I'm headed elsewhere...
  • R
    Rod
    What's the consensus FTM EPS?
  • b
    bob
    Aerie can make you money but not sure if this is the time. 2015 bought at 15.00 and sold in 2017 at 45.00 and aerie do it again???
  • D
    David
    Hey JIM.... how are those prescription #s looking ? Any info., and given time frame ?
  • J
    Jim
    A little more than 16000 bottles this week. About $1.7 million in revenue at 85 per bottle. Not great but not bad either. Interested in seeing how last quarter went. I'm thinking 11 million on revenues.
  • Y
    Yahoo Finance Insights
    Aerie Pharmaceuticals reached a 52 Week low at 10.67
  • D
    David
    And here is what Mizuho securities had to say:
    Aerie Pharmaceuticals price target lowered to $27 from $29 at Mizuho. Mizuho analyst Difei Yang lowered the firm's price target on Aerie Pharmaceuticals to $27 from $29 and keeps a Buy rating on the shares following the company's Q2 results saying net pricing pressures continue

    Read more at:
    https://thefly.com/landingPageNews.php?id=3142293
  • m
    mike
    Limit of 12.50 or market on the close tomorrow.....if a base can build somewhere in the single digits... as Arnold said " I'll Be Back " good luck to all ...
  • R
    Rod
    I'm thinking AERI is a falling knife. I'm waiting 'til it lands on the floor. 30 day envelope shows it is $6.08.
  • D
    David
    Well....Needham kept their BUY rating but lowered the price target from 32 down to 26 per share. Here is the exact quote today:
    08/07/2020 12:34:01 AM Aerie Pharmaceuticals Inc Buy
    The analysts of Needham & Company, LLC have rated Aerie Pharmaceuticals with a Buy rating. The price target was set to $ 26.00. At a current price of $ 12.25 there is upside potential of 112.24%.
  • N
    Newbie
    don't want to be a bag holder.....
  • D
    David
    Jim..... hows the latest bottle count.? prescriptions.... going? (provide a time frame)
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more